Commons Capital LLC Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

Commons Capital LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 290 shares of the company’s stock, valued at approximately $262,000.

A number of other institutional investors and hedge funds have also bought and sold shares of LLY. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter worth about $32,000. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares during the period. Core Wealth Advisors Inc. increased its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Activest Wealth Management bought a new stake in Eli Lilly and Company in the 1st quarter valued at about $39,000. Finally, Tidemark LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $29,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 139,490 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $852.29, for a total value of $118,885,932.10. Following the transaction, the insider now owns 97,869,320 shares in the company, valued at approximately $83,413,042,742.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 876,900 shares of company stock worth $788,605,032 in the last 90 days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $945.00 on Thursday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The stock’s 50 day moving average price is $895.96 and its 200-day moving average price is $826.05. The company has a market capitalization of $898.13 billion, a PE ratio of 139.37, a PEG ratio of 2.91 and a beta of 0.41. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities analysts anticipate that Eli Lilly and Company will post 16.51 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. Eli Lilly and Company’s payout ratio is presently 76.58%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Barclays boosted their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Guggenheim boosted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Berenberg Bank boosted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.